Kuznicki Law PLLC notifies investors that a class action has commenced in the United States District Court for the Southern District of New York on behalf of shareholders of Sarepta Therapeutics, Inc. who purchased shares between September 6, 2017 and August 19, 2019.
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) golodirsen, Sarepta's drug for the treatment of Duchenne muscular dystrophy, posed significant safety risks to patients; (ii) consequently, the New Drug Application package for golodirsen’s accelerated approval was unlikely to receive Food and Drug Administration approval; and (iii) as a result, Sarepta’s public statements were materially false and misleading at all relevant times.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.
Shareholders have until October 29, 2019 to request that the court appoint them lead plaintiff.
To receive more information, please fill out the form.
KUZNICKI LAW PLLC
445 Central Avenue, Suite 344, Cedarhurst, NY 11516
Phone: (347) 696-1134
Cell : (347) 690-0692
Fax : (347) 348-0967
© 2019 All Rights Reserved.